Semaglutide OXY-SEMA (2 mg) OxyPharma

Catalogue entry: Semaglutide OXY-SEMA OxyPharma. Labelled content: 2 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

Semaglutide is a peptide GLP-1 receptor agonist. It is studied in glucose regulation, appetite and body-weight management within specific medicinal formulations. Tirzepatide has an additional GIP-receptor target; Cagrilintide follows an amylin-based pathway. These distinctions explain related research without establishing interchangeable products.

What the research measured

Wilding and colleagues published STEP 1 in the New England Journal of Medicine in 2021. The trial examined adults with overweight or obesity under a defined treatment programme. An exploratory body-composition analysis separately considered fat and lean tissue. Weight reduction is not synonymous with an increase in muscle strength or improved competitive performance.

Sporting claims and limitations

For athletes, appetite and gastrointestinal changes can affect food intake, hydration and training tolerability. The prescribing information of named medicines describes product-specific adverse reactions and precautions. Those clinical documents cannot supply a safety guarantee for an unrelated lyophilised preparation. A familiar active-substance name does not settle formulation, absorption, purity or manufacturing control.

Product identity and documentation

Read the chosen option as the labelled product quantity and presentation. Useful documentation includes the actual manufacturer, lot reference, analytical identity and relevant quality tests. Authorisations for medicines such as Wegovy concern those named products and their conditions of use. They do not authenticate this catalogue item or justify assuming that a separately supplied vial has the same composition and pharmaceutical quality.